New England Biolabs has launched the Monarch Mag Cell-free DNA extraction kit, expanding its nucleic acid purification portfolio with a magnetic bead-based solution designed for scalable and reproducible isolation of circulating cell-free DNA from biofluids.

The product is aimed at researchers working with low-abundance, highly fragmented cfDNA in applications including biomarker discovery and diagnostics development. According to the company, the workflow is compatible with plasma, serum, urine and cerebrospinal fluid and supports variable input volumes from 1 ml to 4 ml. The automation-compatible format is intended to support both low-throughput manual processing and higher-throughput laboratory workflows.

Cell-free DNA extraction presents technical challenges due to fragmentation and low concentrations within complex biofluid matrices. Anagha Kadam, applications and product development scientist II at New England Biolabs, said: “Extracting cell-free DNA is uniquely challenging because it is highly fragmented and circulating at low concentrations within complex and variable biofluid matrices. The kit utilizes a specialized chemistry and silica-coated magnetic beads to efficiently recover short DNA fragments from challenging samples that inherently exhibit high nuclease activity.”

The company said the kit enables recovery of cfDNA fragments down to 50 base pairs in length, supporting downstream sequencing and amplification applications. The chemistry is based on silica-coated magnetic beads and is designed to maintain performance across different sample types and input volumes.

The launch extends the Monarch portfolio into cfDNA extraction, positioning the company to offer a more integrated workflow from sample preparation through to sequencing. James Deng, senior product marketing manager at New England Biolabs, said: “Bouncing between vendors to troubleshoot an issue is exhausting and inefficient. With a cfDNA extraction kit that integrates seamlessly into our downstream sequencing and amplification solutions, we’re empowered to more holistically address customer challenges from sample preparation through molecular diagnostic applications.”

The kit is designed to pair with the company’s downstream amplification and library preparation products, including its NEBNext portfolio for next generation sequencing library preparation. By aligning extraction with sequencing and amplification tools, New England Biolabs is seeking to streamline laboratory workflows and reduce variability introduced by multi-vendor processes.

The company also said the kit reduces plastic usage in reagent bottles and packaging components compared with standard market solutions, reflecting wider sustainability efforts across the Monarch range.

While clearly a commercial product launch, the expansion into cfDNA extraction reflects growing demand for reliable, automation-ready workflows in liquid biopsy research and molecular diagnostics development, where consistency and fragment recovery are critical for analytical performance.